Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke,…

By Gregory Y. H. Lip, L. Frison, J. Halperin, D. Lane. Journal of the American College of Cardiology, 2011

1,096 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, background): “Compared with low-risk patients, moderate-risk patients are assumed to have a twofold risk and high-risk patients are assumed to have an eightfold risk of major bleeding.(79,185,187,189,195,196,198,204) We estimate that anticoagulation is associated with a 2.”
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). (2014, neutral): “CHA2DS2-VASc (8) and HAS-BLED (9) are other methods to assess risk for stroke or bleeding in AF patients.”